Key result
GHRH antagonists demonstrate antitumorigenic actions.
Key points are not available for this paper at this time.
No immediate clinical role in oncology; extends preclinical evidence on GHRH antagonists.
Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans the biological, physical, and social sciences.
No takes yet. Share an insight, caveat, or question.
Rhonda D. Kineman (2000) studied this question. Growth hormone-releasing hormone antagonists demonstrate antitumorigenic actions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: